PSTI Pluristem Therapeutics


Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 1, 2021, Pluristem Therapeutics Inc., or the Company, held its 2021 Annual Meeting of Stockholders, or the 2021 Annual Meeting. The results of stockholder voting at the 2021 Annual Meeting are set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director NameForAgainstAbstainBroker Non-Votes
Zami Aberman9,921,167173,25910,6175,220,994
Mark Germain5,755,3504,338,86810,8255,220,994
Moria Kwiat6,001,4214,093,06110,5615,220,994
Maital Shemesh-Rasmussen9,988,263104,99011,7945,220,990
Rami Levi9,905,005189,25810,7885,220,985
Doron Shorrer5,717,7944,376,45010,7955,220,998
Yaky Yanay9,918,727175,81510,5015,220,994

Proposal No. 2 — Ratification of the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2021.

ForAgainstAbstainBroker Non-Votes

Proposal No. 3 —Approval, by a nonbinding advisory vote, of the compensation of the Company’s named executive officers.

ForAgainstAbstainBroker Non-Votes

The results reported above are final voting results.